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The goal of the study was to identify brain and functional features associated with premanifest
phases of adult-onset myotonic dystrophy type 1 (i.e., PreDM1).
Methods
This cross-sectional study included 68 healthy adults (mean age = 43.4 years, SD = 12.9), 13
individuals with PreDM1 (mean age: 47.4 years, SD = 16.3), and 37 individuals with manifest
DM1 (mean age = 45.2 years, SD = 9.3). The primary outcome measures included fractional
anisotropy (FA), motor measures (Muscle Impairment Rating Scale, Grooved Pegboard,
Finger-Tapping Test, and grip force), general cognitive abilities (Wechsler Adult Intelligence
Scales), sleep quality (Scales for Outcomes in Parkinson’s Disease–Sleep), and apathy (Apathy
Evaluation Scale).
Results
Individuals with PreDM1 exhibited an intermediate level of white matter FA abnormality,
where whole-brain FA was lower relative to healthy controls (difference of the estimated
marginal mean [EMMdifference] = 0.02, 95% confidence interval (CI) 0.01–0.03, p < 0.001), but
the PreDM1 group had significantly higher FA than did individuals with manifest DM1
(EMMdifference = 0.02, 95% CI 0.009–0.03, p < 0.001). Individuals with PreDM1 exhibited
reduced performance on the finger-tapping task relative to control peers (EMMdifference = 5.70,
95% CI 0.51–11.00, p = 0.03), but performance of the PreDM1 group was better than that of
the manifest DM1 group (EMMdifference = 5.60, 95% CI 0.11–11.00, p = 0.05). Hypersom-
nolence in PreDM1 was intermediate between controls (EMMdifference = −1.70, 95% CI
−3.10–0.35, p = 0.01) and manifest DM1 (EMMdifference = −2.10, 95% CI −3.50–0.60, p =
0.006).
Conclusions
Our findings highlight key CNS and functional deficits associated with PreDM1, offering
insight in early disease course.
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Myotonic dystrophy type 1 (DM1) is an autosomal dominant
trinucleotide repeat disorder caused by a CTG repeat ex-
pansion in the DMPK gene. Symptom manifestation of adult-
onset DM1may be preceded by a prodromal phase, similar to
Huntington disease (HD) where motor manifestation is
preceded by changes in brain morphology, cognition, be-
havior, and motor function.1–3 Formulas that include age and
trinucleotide repeat length have been developed for the pre-
symptomatic phases of HD to determine proximity to disease
onset and progression. Proximity to HD onset is correlated
with reduced striatal volume, the most sensitive MRI measure
of HD motor onset.3–8 A Dutch group introduced the notion
that some carriers of the DM1 mutation lacked diagnostic
signs.9 Several studies have subsequently evaluated swallow-
ing10 and eye movement11 in presymptomatic patients with
DM1. Collectively, little is known about the presymptomatic
phase of DM1 (PreDM1), particularly regarding brain mor-
phology, or the potential utility of an age by CTG product for
estimating disease burden.
Several key features require exploration in the context of
PreDM1. Reduced white matter (WM) fractional anisotropy
(FA) in patients with DM1 relative to controls is a prominent
feature of CNS abnormality.12–21 Cognitive challenges are
also prevalent in adult-onset DM122 and encompass mild to
moderate intellectual impairment, executive dysfunction, and
visuospatial difficulty.23 Apathy is substantially more preva-
lent in adults with DM1 than unaffected adults.24 Finally,
hypersomnolence is evident in approximately 30%–60% of
patients, making it one of the most frequent nonmuscular
symptoms.25
First, we identified brain WM FA and functional measures—
including motor skill, general cognitive abilities, somnolence,
and apathy—associated with PreDM1. Second, we evaluated
the utility of a CTG by age product to approximate disease
burden in regard to brain imaging measures.
Methods
Participants
Individuals with DM1 were recruited consecutively to par-
ticipate in the Iowa DM1–Brain and Muscle study in Iowa
City, Iowa, via advertisements through the advocacy group
The Myotonic Dystrophy Foundation and word of mouth.
Healthy control participants were recruited from the Iowa
City area via advertisements or as a spouse/partner of par-
ticipants with DM1. Exclusion criteria for all participants in-
cluded MRI contraindication, a history of serious head injury,
or a chronic neurologic disorder other than DM1. Control
participants were additionally required to be without history
of substance abuse, psychiatric disease, or major medical
disease. Recruitment was targeted to adult-onset DM1 only
(onset after age 18 years). Individuals who reported disease
onset DM1 before age 18 years were excluded. The groups
consisted of 61 controls, 45 subjects who had been geneti-
cally confirmed to have the gene expansion (CTG ≥50) for
DM1, and 12 with a family history of DM1 without con-
firmative testing (i.e., at risk). These at-risk participants
underwent genetic testing for research purposes only. At-risk
individuals who were determined to have CTG repeat length
≥50 were included in the DM1 group (N = 5); the remainder
were included in the control group (N = 7). The final sample
included 118 individuals (68 controls and 50 DM1). Re-
cruitment took place between March 2016 and February
2020.
PreDM1 was operationally defined by the absence of de-
tectable motor symptoms as determined by a clinical exami-
nation by neuromuscular neurologist using the Muscle
Impairment Rating Scale (MIRS). The MIRS ranges from 1
(normal, no symptoms) to 5 (severe symptoms). We chose
this definition to operationalize our analysis; however, we
understand that the onset of DM1 is not always clear. Some
patients may have, for example, cataracts, sleepiness, or apa-
thy, but no motor symptoms. Some patients may also have
mild motor symptoms subjectively that do not manifest by a
clinical examination.26 From our sample of 50 subjects with
DM1, 13 of them had anMIRS = 1 and were therefore defined
as preDM1, with the remaining 37 subjects defined as mani-
fest DM1.
Standard Protocol Approvals, Registrations,
and Patient Consents
All data were deidentified, and all participants consented to
nondisclosure of genetic results obtained as part of the study.
All participants gave written informed consent before en-
rolling in the protocol. The study was approved by the Uni-
versity of Iowa Institutional Review Board.
Genetics: Estimated Progenitor Allele Length
and Detection of Variant Repeats
Genotyping of pre- and manifest DM1 participants was com-
pleted by small-pool PCR (SP-PCR).27 For each participant, 4
reactions were completed, each using 300 pg genomic DNA
template derived from blood leukocytes. The primers used
were (forward) DM-C (59 AACGGGGCTCGAAGGGTCCT
39) and (reverse) DM-DR (59 CAGGCCTGCAGTTTGCC-
CATC 39). CTG repeat lengths were estimated by comparison
Glossary
AES = Apathy Evaluation Scale; DM1 = myotonic dystrophy type 1; EMM = estimated marginal mean; ePAL = estimated
progenitor allele length; FA = fractional anisotropy; FDR = false discovery rate; HD = Huntington disease; MIRS = Muscle
Impairment Rating Scale; PreDM1 = presymptomatic phase of DM1; SP-PCR = small-pool PCR; WM = white matter.
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against DNA fragments of known length and molecular weight
markers, using CLIQS software (TotalLabs UK Ltd., New-
castle upon Tyne, United Kingdom). The lower boundary of
the expanded molecules in SP-PCR was used to estimate the
progenitor (or inherited) allele length (ePAL).28 Patients with
CCG interruptions (referred to as variant repeats) have been
shown to have a substantially milder form of DM1 compared
with patients with pure repeats.29 Therefore, we also evaluated
small-pool PCR products from all participants for AciI sensi-
tivity (New England BioLabs UK Ltd., Hitchin, United King-
dom; restriction site 59CCGC-39) allowing identification of
participants with variant repeats, as previously described.30 For
patients with variant repeats, as for those with pure CTG repeat
expansions, ePAL was defined as the total length of triplet
repeats (whether CTG, CCG, or other triplet motifs) as de-
termined from the lower boundary of bands on the SP-PCR
blot. This estimate was used because AciI sensitivity alone
cannot be used to infer the precise number or location of
variant repeats or to determine the length of the longest stretch
of pure CTG repeats present.
Genetics: Determination of CTG Repeat Length
in Control Participants
CTG repeat length was estimated by MiSeq sequencing, es-
sentially as described for HD alleles,31 substituting DM1-for
HD-specific primers, and using reference sequences
Table 1 Sample Characteristics
Healthy adults (N = 68) PreDM1 (N = 13) DM1 (N = 37)
Sex, n (%)
Female 45 (66.2) 7 (53.8) 26 (70.3)
Male 23 (33.8) 6 (46.2) 11 (29.7)
Age, y
Mean (SD) 43.4 (12.9) 47.4 (16.3) 45.2 (9.27)
Median [min, max] 43.7 [18.3, 63.4] 53.3 [19.2, 64.0] 44.1 [30.3, 62.2]
Age of symptom onset, y
Mean (SD) — — 32.7 (10.1)
Median [min, max] — — 32.0 [16.0c, 52.0]
Education, y
Mean (SD) 16.1 (2.07) 15.8 (1.83) 15.8 (2.24)
Median [min, max] 16.0 [12.0, 20.0] 16.0 [13.0, 20.0] 16.0 [12.0, 20.0]
ePALa
Mean (SD) 13.9 (6.13) 102 (59.1) 180 (97.4)
Median [min, max] 13.0 [5.00, 43.0] 85.0 [55.0, 276] 146 [67.0, 501]
Missing, n (%) 1 (1.5) 0 (0) 1 (2.7)
Variant repeats, n (%)b
Controls 68 (100) 0 (0) 0 (0)
Pure 0 (0) 12 (92.3) 33 (89.2)
Variant 0 (0) 1 (7.7) 4 (10.8)
Muscle Impairment Rating Scale, n (%)
1 0 (0) 13 (100) 0 (0)
2 0 (0) 0 (0) 25 (67.6)
3 0 (0) 0 (0) 9 (24.3)
4 0 (0) 0 (0) 2 (5.4)
Abbreviations: DM1 = myotonic dystrophy type 1; ePAL = estimated progenitor allele length; PreDM1 = presymptomatic phase of DM1.
a For alleles <50, the value represents the absolute length of the longest inherited allele.
b Refers to naturally occurring interruptions in the CTG repeat tract that has been associated with a milder phenotype.
c One individual reported mild hand myotonia at age 16 years, but no other symptoms.
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comprising 0 to 100 CTG repeats and 59- and 39-flanking
sequence to the primer binding sites.
MRI
Participants who participated before June 2016 (N = 52, 24
controls, 28 DM1) were scanned using a 3T Siemens Tri-
oTIM scanner. Those who participated after June 2016 (N =
66, 34 controls, 22 DM1) were scanned using a 3T General
Electric Discovery MR750w scanner.
Batch effects in diffusion-weighted images associated with
scanner versions were normalized using ComBat harmoni-
zation (see figure e-1, links.lww.com/NXG/A406).32
Diffusion-weighted images were collected using echo planar
recovery magnitude sequences collected in the axial plane
with either a single shell (B1000, 64 directions), multishell
(B1000 and B2000, 29–30 directions per shell), or both
(details provided in table e-1, links.lww.com/NXG/A406).
White Matter FA
Diffusion-weighted images were processed using standard
procedures of the FMRIB Diffusion toolbox from the FSL
software package (fmrib.ox.ac.uk/fsl), where phase encoding
distortion and eddy current artifacts were removed.33,34 Diffu-
sion tensor models were generated using dtifit, and diffusivity
measures, including FA, were calculated. To normalize scalars to
a common space, the following registrations were performed
using rigid, affine, and nonlinear (symmetric normalization)
components using Advanced Normalization Tools35: (1) B0
images (after encoding distortion and artifacts are removed)
were registered to T2w images in native space (not to T1w
images, since B0 and T2w images have similar intensity distri-
butions by tissue type, which improves registration accuracy).
(2) For more accurate anatomic registrations, T2w images were
coregistered to T1w images in native, individual space. Finally,
(3) for accurate normalization, both T1w and T2w coregistered
images were registered simultaneously to coregistered, same-
modality images in template space. These transformations were
applied to FA maps in a single linear interpolation step to
prevent compounding interpolation errors.
Motor Function
The MIRS is an expert rating tool established in accordance
with the clinically recognized distal to proximal progression of
muscle impairment in DM1.36
Fine motor skills were measured with the finger-tapping and
the grooved Pegboard tests (Lafayette Instruments, Lafayette,
LA). Participants completed 5 consecutive 10 second tap
trials. The dependent variable was the average number of taps
using the dominant hand. The Grooved Pegboard test re-
quires participants to insert keyed pegs into slots. The out-
come measure of interest was time in seconds, to completion
using the dominant hand. The Lafayette Instruments dyna-
mometer was used to assess grip force in kilogram force. The
dependent variable represents the average grip force of the
dominant hand across 3 trials.
General Cognitive Abilities
Participants completed the Wechsler Adult Intelligence Scale
IV to estimate verbal comprehension, perceptual reasoning,
working memory, and processing speed.37
Sleep Quality
The Scales for Outcomes in Parkinson’s Disease–Sleep survey
was used to assess sleep quality.38 The self-report scale in-
cludes 5 nighttime sleep quality items and 6 hypersomnolence
items, which were summed to calculate total sleep quality and
hypersomnolence scores.
Apathy
The Apathy Evaluation Scale (AES) was used to determine self-
reported degree of apathy.39 The AES includes 18 items that are
rated on a 4-point Likert scale. Items were summed to create a
total score, where higher scores represent increased apathy.
Statistical Analysis
Demographic characteristics of the DM1 group and the
control group were summarized with descriptive statistics.
Figure 1 WM FA Across Groups
Panel A shows that whole-brainWM FA is shown on the x-axis across groups
(controls, PreDM1, and manifest DM1). Estimated marginal means are
represented as diamonds with associated 95% confidence limits. Small cir-
cles represent individual observations. Significant differences between
groups at p < 0.05 are marked with black, vertical bars. Whole-brain WM FA
in PreDM1 was intermediate between that of control individuals and pa-
tients with manifest DM1. Panel B shows a voxel-wisemap of FA differences
between the control group andPreDM1 group. Panel C shows FA differences
between the control group and the manifest DM1 group. DM1 = myotonic
dystrophy type 1; FA = fractional anisotropy; PreDM1 = presymptomatic
phase of DM1; WM = white matter.
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Group differences in functional outcomes and WM FA values
were examined using a linearmixed effects framework, where the
random effect of family and fixed effects of group controls vs
PreDM1 vs manifest DM1, age, and sex were included in each
model. Wald tests were applied to assess effects of grouping
variables with more than 2 levels, and the false discovery rate
(FDR) was applied to account for multiple comparisons.40 Re-
sults were displayed as estimated marginal means (EMMs) or as
the difference in EMM (EMMdifference). The age*ePAL product
was computed and examined in relationship to whole-brainWM
FA within individuals with PreDM1 and in DM1.
Data Availability
Data can be shared on reasonable request.
Results
Sample
The sample included 68 control individuals (33.8% male), 13
individuals with PreDM1 (46.2% male), and 37 individuals with
manifest DM1 (29.7% male; table 1). There were fewer males
than females (χ2(1) = 12.237, p = 0.0005); however, the sex
distribution was similar across groups (χ2(2) = 1.159, p = 0.560).
Age at evaluation and education were also comparable across
groups (F(2,115) = 0.66, p = 0.519; F(2,115) = 0.27, p = 0.766,
respectively). ePALwas significantly longer in themanifest DM1
group relative to the PreDM1 group (Χ(2)
2 = 86.98, p = 7.9 ×
10−5). One individual with PreDM1 and 4 individuals withDM1
were identified as having a variant repeat.
Figure 2 ePAL Characteristics of Subset of Patients With DM1
Panel A shows the distribution of the natural log of
ePAL (x-axis) across groups (y-axis). Individuals
with ePAL (estimated progenitor allele length)
greater than 125 repeats were excluded (manifest
DM1 = 14; PreDM1 = 1), resulting in a group of 12
individuals with PreDM1 and 22 individuals with
manifest DM1with comparable ePAL repeats. The
dotted, vertical line represents the cutoff for cre-
ating subgroups with comparable ePAL. The open
circles represent observations that were excluded
from the subset analysis. Panel B shows whole-
brainWM FA on the x-axis and group on the y-axis.
Estimated marginal means are shown as dia-
monds with associated 95% confidence limits. The
analyses included participants with DM1 with
comparable ePAL repeats. The findings re-
capitulate those of the full sample: cerebral FA of
the PreDM1 group is intermediate between that of
controls and individuals with manifest DM1. The
vertical bars highlight pairwise comparisons that
were statistically significant at p < 0.05. DM1 =
myotonic dystrophy type 1; ePAL = estimated
progenitor allele length; PreDM1 = pre-
symptomatic phase of DM1; WM = white matter.
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White Matter FA
The PreDM1 group exhibited an intermediate level of WM
FA abnormality: whole-brain FA was lower relative to con-
trols (EMMPreDM1 = 0.39, EMMcontrol = 0.42, EMMdifference =
0.02, p < 0.001), but the PreDM1 group had significantly
higher FA than did individuals with manifest DM1 (EMMDM1
= 0.37, EMMdifference = 0.02, p < 0.001; figure 1A). On aver-
age, whole-brain WM FA in the PreDM1 group was ;6%
lower than that of the control group and;5% higher than the
manifest DM1 group. Figure 1B highlights voxel-wise FA
differences between the control group and PreDM1 and be-
tween manifest DM1 and controls (figure 1C). The pattern
for both is widespread changes with the greatest changes
being in frontal regions. Group differences between regional
WM FA are shown in figure e-2 (links.lww.com/NXG/
A406). Similar to the voxel-wide analysis, most regions are
affected with the anterior aspects of the corpus callosum
(genu) having the highest level of abnormality.
Note that removal of the 5 individuals (PreDM1= 1;DM1= 4)
with variant repeats did not result in significant changes
(controls vs PreDM1: EMMdifference = 0.02, controls vs DM1 =
0.04, PreDM1 vs DM1 = 0.02).
To explore the potential impact of differences in ePAL be-
tween PreDM1 and manifest DM1, analyses were repeated in
a subset of patients with DM1 with comparable ePAL (figure
2A; PreDM1 = 12 [mean age = 49.55 years, SD = 14.99];
manifest DM1 = 22 [mean age = 47.95 years, SD = 9.26]). As
with the full sample, the PreDM1 group exhibited lower
whole-brain WM FA than the control group (EMMdifference =
0.019, 95%, p < 0.001) and higher whole-brain WM FA than
the manifest DM1 group (EMMdifference = 0.020, p = 0.002;
figure 2B).
Functional Outcomes
Group differences were significant for all measures, except
verbal comprehension and sleep quality (all, pFDR < 0.05;
table 2). In general, the PreDM1 group was intermediate
between the control group and manifest DM1 (figure 3).
Significant differences between PreDM1 and controls were
noted for finger tapping (EMMdifference = 5.70, p = 0.03) and
hypersomnolence (EMMdifference = −1.70, p = 0.01). Differ-
ences between PreDM1 and manifest DM1 were statistically
significant for finger tapping (EMMdifference = 5.60, p = 0.05)
and hypersomnolence (EMMdifference = −2.10, p = 0.006).
Comparisons between the PreDM1 and the manifest DM1
group also showed significant differences on other functional
measures (table 2), including apathy, Perceptual Reasoning
Index scores, Processing Speed Index scores, Full-Scale IQ,
Pegboard, and grip strength. The manifest DM1 consistently
had poorer outcomes than did the PreDM1 group. Differ-
ences between controls and individuals with manifest DM1
were all significant (all, p < 0.01), except for sleep quality (p =
0.91; table 2 and figure 3).
Association Between WM FA and Proxy for
Disease Burden
The age*ePAL product was computed as a proxy for disease
burden, and its association with whole-brain WM FA was
explored within individuals with PreDM1 and in DM1.
Table 2 Functional Outcomes Across Groups
Main group effecta Controls–PreDM1 Controls–DM1 PreDM1–DM1
χ2(2) p Value pFDR Value EMMdiff 95% CI EMMdiff 95% CI EMMdiff 95% CI
WRAT—Scaled Score 9.59 0.008 0.05 3.10 −3.30 to 9.50 7.60 2.60 to 13.00 4.50 −1.30 to 10.00
Apathy Self-Score 25.70 <0.001 <0.001 −1.50 −4.90 to 2.00 −6.10 −8.60 to 3.70 −4.70 −8.20 to 1.10
Verbal comprehension 9.84 0.007 0.05 1.90 −4.50 to 8.20 7.30 2.60 to 12.00 5.40 −0.98 to 12.00
Perceptual reasoning 30.90 <0.001 <0.001 −3.90 −11.00 to 3.40 13.00 7.60 to 18.00 17.00 8.80 to 24.00
Working memory 16.04 0.0003 0.002 4.60 −3.60 to 13.00 11.00 5.70 to 17.00 6.60 −2.10 to 15.00
Processing speed 18.93 <0.001 0.0005 0.43 −7.40 to 8.20 12.00 6.10 to 17.00 11.00 2.90 to 19.00
Full-Scale IQ 29.36 <0.001 <0.001 1.10 −5.90 to 8.00 13.00 8.00 to 18.00 12.00 4.50 to 19.00
Pegboard 16.61 <0.001 0.001 −2.30 −11.00 to 6.50 −12.00 −18.00 to 6.30 −10.00 −19.00 to 0.68
Finger tapping 40.48 <0.001 <0.001 5.70 0.51 to 11.00 11.00 7.80 to 15.00 5.60 0.11 to 11.00
Grip strength 41.99 <0.001 <0.001 4.80 −1.90 to 11.00 15.00 10.00 to 19.00 9.90 2.80 to 17.00
Sleep quality 1.78 0.41 1 −0.61 −2.20 to 1.00 −0.71 −1.80 to 0.40 −0.10 −1.80 to 1.60
Hypersomnolence 64.07 <0.001 <0.001 −1.70 −3.10 to 0.35 −3.80 −4.80 to 2.90 −2.10 −3.50 to 0.60
Abbreviations: CI = confidence interval; DM1 = myotonic dystrophy type 1; EMMdiff = difference of estimated marginal mean; FDR = false discovery rate;
PreDM1 = presymptomatic phase of DM1; WRAT = Wide Range Achievement Test.
a Represents summary statistics for group coefficient in the model.
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Whole-brain WM FA was significantly predicted by age*ePAL
in the PreDM1 group (t(10) = −2.87, p = 0.02), suggesting that a
large age*ePAL product was significantly associated with lower
whole-brain WM FA (figure 4). In contrast, the age*ePAL
product did not significantly predict whole-brain WM FA
among individuals with DM1 (t(29) = −1.22, p = 0.2; figure 4).
Discussion
In almost all measures, we found that the PreDM1 group was
generally intermediate between healthy controls and indi-
viduals with manifest DM1. In particular, compared with
controls, subjects with PreDM1 had significantly (1) lower
brain FA; (2) poorer finger-tapping scores; and (3) higher
self-ratings of hypersomnolence. These findings support the
notion that among DM1 mutation carriers, changes in the
brain, finemotor skills, and sleep may precede the onset of the
classic clinical motor signs.
Premanifest DM1 was defined based on the absence of motor
signs and symptoms as measured with the MIRS, which is
commonly used for monitoring DM1 stage and progression.
Although our definition did not encompass nonmuscular
symptoms that are known to be associated with DM1 (e.g.,
cataracts),41 a precise definition of disease manifestation in DM1
is challenging given the multisystemic nature of the disease.
Nonetheless, muscle impairment remains a key defining feature
of DM1, making MIRS a useful proxy for disease manifestation.
Reduced WM FA is one of the most reproducible findings in
the DM1 literature,12 and we showed that reductions in WM
Figure 3 Functional Outcomes Across Groups
Each panel lists the functional measure at the top, with scores on the y-axis for controls (white), PreDM1 (gray), andmanifest DM1 (black). Estimatedmarginal
means and associated 95% confidence limits are shown. The horizontal lines highlight pairwise comparisons that were statistically different at p < 0.05. DM1 =
myotonic dystrophy type 1; FSIQ = Full-Scale IQ; PreDM1 = presymptomatic phase of DM1; PRI = perceptual Reasoning Index; PSI = Processing Speed Index;
VCI = Verbal Comprehension Index; WMI = Working Memory Index; WRAT = Wide Range Achievement Test.
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FA precede clinical motor signs and symptoms associated
with DM1. Moreover, we noted that an estimate of disease
burden, age*ePAL product, was highly predictive of FA
measures in the PreDM1 sample—those with the highest
disease burden (a proxy to time to onset) had the lowest FA
values. These results suggest that WM FA may be useful in
tracking disease progress before clinical symptoms parallel to
the way striatal volume tracks and predicts motor onset in
HD.42 The age*ePAL did not predict FA in the manifest
phase, which could mean that by the time of motor onset, FA
has declined so far that there may be a floor effect for pre-
dicting further change using this index. The present sample of
Figure 4 Relationship Between ePAL*Age Product and Whole-Brain WM FA Among Individuals With DM1 and PreMD1
Panel A shows the relationship between age*ePAL product (x-axis) and whole-brain WM FA (y-axis) for the PreDM1 group, and panel B shows the same
relationship for individuals with manifest DM1. DM1 = myotonic dystrophy type 1; ePAL = estimated progenitor allele length; FA = fractional anisotropy;
PreDM1 = presymptomatic phase of DM1; WM = white matter.
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manifest DM1 had a median MIRS score of 2, indicating that
as a group, these patients were very early in the course of
disease, yet their WM FA was a full 10% lower than healthy
controls. Our novel estimate of disease burden requires fur-
ther investigation to establish its utility in predicting disease
onset.
Individuals with PreDM1 exhibited significantly more diffi-
culty with the finger-tapping test than did controls, suggesting
that this quantitative measure of fine motor skill may be quite
sensitive to early brain changes in addition to primary muscle
dysfunction. Abnormalities in similar finger-tapping tasks also
are reported as some of the earliest changes in individuals with
PreHD and speeded finger-tapping paradigms appear partic-
ularly useful in detecting such changes in motor function.43
Evaluation of fine motor skills among individuals in pre-
manifest stages of DM1 will be important in determining
markers of disease progression.
Hypersomnolence also appeared to precede muscle impair-
ment. Although this is a self-reported measure and not a
quantitative assessment, excessive daytime sleepiness has been
considered one of the most troublesome and disabling features
of the disease. Future studies might involve monitoring of
objective measures of wakefulness such as using monitors that
track movement/activity or direct assessment of EEG.
Our findings should be considered with several limitations. As
noted previously, our definition of PreDM1 is limited to
clinical motor signs and symptoms. Some subtle manifesta-
tions of clinical symptoms may not have been detected with
the clinical examination we used to determine a patient’s
status. Second, the sample included a small number of pre-
manifest individuals with DM1, limiting statistical power.
DM1 being a rare disorder, it is challenging to recruit a large
sample at a single institute. Multisite efforts are required to
gain insight into CNS involvement in DM1. Third, ePAL
differed significantly between the PreDM1 group and the
manifest DM1 group. This difference could be related to
participation bias, where patients who are healthy enough to
participate in research are also likely less affected by the dis-
ease. Limiting the analyses to DM1 groups with comparable
ePAL recapitulated the pattern observed in the entire sample,
suggesting that the observed differences between PreDM1
and manifest DM1 were not explained by ePAL differences
alone. Fourth, our study design was cross-sectional, and lon-
gitudinal studies evaluating changes in brain structure and
function are essential for understanding disease progression.
Longitudinal assessment will be particularly important in
establishing if FA, speeded finger tapping, and hypersomno-
lence are useful in predicting motor onset among premanifest
patients.
The present study identified brain and functional changes in
premanifest DM1 as defined by the absence of clinically de-
termined motor symptoms. Further studies are needed to
replicate and extend our findings.
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